Conexeu Sciences, Inc. (CNXU)
3.90
+0.45
(+13.04%)
USD |
NASDAQ |
Oct 09, 16:00
3.86
-0.04
(-1.03%)
After-Hours: 20:00
Conexeu Sciences Enterprise Value : 92.38M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 92.38M |
| October 07, 2026 | 97.59M |
| October 06, 2026 | 98.14M |
| October 05, 2026 | 83.34M |
| October 02, 2026 | 82.79M |
| October 01, 2026 | 88.82M |
| September 30, 2026 | 95.67M |
| September 29, 2026 | 99.51M |
| September 28, 2026 | 101.15M |
| September 25, 2026 | 104.44M |
| September 24, 2026 | 106.36M |
| September 23, 2026 | 113.21M |
| September 22, 2026 | 118.41M |
| September 21, 2026 | 128.00M |
| September 18, 2026 | 133.75M |
| September 17, 2026 | 143.07M |
| September 16, 2026 | 124.44M |
| September 15, 2026 | 119.78M |
| September 14, 2026 | 134.85M |
| September 11, 2026 | 120.05M |
| September 10, 2026 | 114.30M |
| September 09, 2026 | 120.05M |
| September 08, 2026 | 126.08M |
| September 04, 2026 | 134.03M |
| September 03, 2026 | 142.25M |
| Date | Value |
|---|---|
| September 02, 2026 | 150.19M |
| September 01, 2026 | 158.68M |
| August 31, 2026 | 194.44M |
| August 28, 2026 | 191.56M |
| August 27, 2026 | 190.74M |
| August 26, 2026 | 188.96M |
| August 25, 2026 | 204.71M |
| August 24, 2026 | 211.84M |
| August 21, 2026 | 241.42M |
| August 20, 2026 | 256.22M |
| August 19, 2026 | 243.34M |
| August 18, 2026 | 271.56M |
| August 17, 2026 | 265.81M |
| August 14, 2026 | 241.70M |
| August 13, 2026 | 216.22M |
| August 12, 2026 | 198.14M |
| August 11, 2026 | 201.70M |
| August 10, 2026 | 197.04M |
| August 07, 2026 | 218.96M |
| August 06, 2026 | 229.92M |
| August 05, 2026 | 244.16M |
| August 04, 2026 | 246.63M |
| August 03, 2026 | 210.47M |
| July 31, 2026 | 225.53M |
| July 30, 2026 | 228.97M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 545.69B |
| Vericel Corp. | 1.982B |
| ACADIA Pharmaceuticals, Inc. | 2.488B |
| Alnylam Pharmaceuticals, Inc. | 29.71B |
| Anika Therapeutics, Inc. | 244.19M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.726M |
| Total Expenses (Quarterly) | 7.726M |
| EPS Diluted (Quarterly) | -0.282 |
| Earnings Yield | -11.74% |